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Killer-cell immunoglobulin-like receptors (KIRs) are a family of cell surface proteins found 
on natural killer cells, which are components of the innate immune system. KIRs rec-
ognize MHC class I proteins, mainly HLA-C and are further divided into two groups: 
short-tailed 2/3DS activating receptors and long-tailed 2/3DL inhibitory receptors. 
Based on the Barker Hypothesis, the origins of illness can be traced back to embry-
onic development in the uterus, and since KIR:HLA interaction figures prominently in 
the maternal–fetal interface, we investigated whether specific KIR:HLA combinations 
may be found in autism spectrum disorders (ASD) children compared with their healthy 
parents. This study enrolled 49 ASD children from different Israeli families, and their 
healthy parents. Among the parents, a higher frequency of HLA-C2 allotypes was found 
in the fathers, while its corresponding ligand 2DS1 was found in higher percentage in the 
maternal group. However, such skewing in KIR:HLA frequencies did not appear in the 
ASD children. Additionally, analysis of “overall activation” indicated higher activation in 
maternal than in paternal cohorts.
Keywords: autism, pregnancy, natural killer, Kir, hla
inTrODUcTiOn
Autism spectrum disorders (ASD) encompass a range of neurodevelopmental syndromes defined by 
difficulties in social communication and stereotyped behaviors (1). Recent data indicate a prevalence 
of up to 1 in 66 children (2). Although studies in families and twins (3) point toward a significant 
genetic component with a high sibling recurrence risk (4), in only a few cases can a clear genetic 
component be identified. Various factors – hormonal, immunological, and biochemical – have been 
implicated in autism’s etiology, but their roles in the symptomology of the disease remain undefined 
(5). Immune system dysregulation reported in ASD patients includes differential cell fractions and 
reactivity, autoimmune phenomena, altered cytokine and antibody profiles, and genetic correlations 
(6). These findings partially corroborate the theory that chronic neurological inflammation in fetal or 
newborn brain underlies the development of ASD. Subsequent dysregulation of the immune system 
may contribute to ASD development in genetically susceptible children.
Abbreviations: ASD, autism spectrum disorders; HLA, histocompatibility leukocyte antigens; KIR, killer-cell immunoglobulin-
like receptor; NK, natural killer.
2DS2 2DL2 2DL3 2DL1 3DS1 2DS1 2DS4 3DL1 3DL2
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FigUre 1 | schematic diagram of activating (green) and inhibitory (red) receptors on natural killer cells, arranged according to centromic/telomeric 
location. These receptors are known to interact specifically with HLA ligands (HLA CI or C2, HLA A and B BW4). HLA-C group 1 (CI) allotypes serve as ligands for 
KIRs 2DS2, 2DL2, and 2DL3; HLA-C group 2 (C2) functions as ligands for KIRs 2DL1 and 2DS1.
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Altered natural killer (NK) cell activity has been reported 
in the periphery of ASD patients (7). However, these innate 
immune cells’ function in the pathogenesis of autism is yet 
unclear. NK cells act specifically against infected or transformed 
cells, with their actions governed by a balance between activating 
and inhibitory receptors, each recognizing specific molecules on 
a given target (8). Killer-cell immunoglobulin-like receptors 
(KIRs) are a group of cell surface molecules involved in regu-
lating activity of NK (and some T) cells. KIRs are classified as 
either inhibitory or activating. Their nomenclature is based on 
the number of extracellular Ig-like domains, and whether the 
cytoplasmic domain is long (L) or short (S). The KIR gene fam-
ily is clustered within the LRC leukocyte receptor complex on 
chromosome 19q13.4, encoding a total of 14 genes and 2 pseudo 
genes. KIR genes exhibit allelic and haplotypic variability, while 
each mature NK cell expresses a specific set of KIRs.
Killer-cell immunoglobulin-like receptor counterparts, the 
HLA class I ligands, are also extremely polymorphic. This gener-
ates an additional level of functional diversity. Both KIRs and 
their HLA ligands are encoded on different chromosomes (19 
and 6, respectively), and therefore segregate independently of 
each other. This expands the repertoire of possible profiles within 
any given population (9). Specific KIR–HLA combinations have 
been suggested as underlying susceptibility as well as resistance to 
various diseases and conditions (10); the functional implications 
are less clear. Genetic associations have been reported in infec-
tious diseases (11), autoimmunity (12), inflammatory conditions, 
reproductive failure, and cancer. Biological models in such stud-
ies need to incorporate these receptor:ligand interactions, beyond 
mere consideration of KIR–HLA genotyping. Indeed, several 
methods have been proposed to analyze the overall genotyping 
detected in a specific subject or whole population (13, 14).
The KIR family predominantly recognizes HLA class I 
molecules. Specifically, HLA-C is recognized by both inhibitory 
receptors (KIRs 2DL1, 2DL2, and 2DL3) and activating receptors 
(KIRs 2DS1, 2DS2, and 2DS4) (Figure 1). HLA-C group 1 (C1) 
allotypes have an asparagine residue at position 80 (C1:N80), and 
serve as ligands for KIRs 2DL2, 2DL3, and 2DS2. HLA-C group 
2 (C2) allotypes function as ligands for KIRs 2DL1 and 2DS1; C2 
allotypes have a lysine at position 80 (C2:K80). The interactional 
affinities of these groups may differ. KIR 2DS4 can bind to both 
HLA-C C1 and C2 allotypes, and certain HLA-A alleles. KIRs 
3DL1 and (putatively) 3DS1 interact with HLA-A BW4:I80 as 
well as HLA-B allotypes [with either isoleucine (BW4:I80) or 
threonine (BW4:T80) at position 80].
The aim of our research was to genotype the KIR receptors 
known to interact with HLA ligands in autistic children and their 
non-autistic parents (mothers and fathers, separately), and to 
compare KIR receptor: HLA ligand frequencies between these 
groups. Our hypothesis was that a non-random distribution of 
these genes profiles should be found if interactions between these 
two classes of molecules are relevant to autism.
According to the Barker Hypothesis (15), the source of pathol-
ogies – including mental disorders such as ASD – can be traced 
back to embryonic existence in the intrauterine environment (16, 
17). KIRs are expressed by maternal NK cells (decidua, uterine 
lining), which are in close contact with HLA-expressing fetal tis-
sues (placenta). Such prenatal interaction between maternal KIR 
and the fetal HLA in the uterus may lead to either enhanced NK 
activation or NK inhibition, which in turn may exert influence 
upon the placenta and/or developing fetus (18–20). Resulting 
immune activation and effects upon the central nervous system 
may lead to neurological and psychiatric disorders in predisposed 
patients. A mouse model for intrauterine maternal immune acti-
vation has already been demonstrated as a possible mechanism 
for autism- and schizophrenia-related behaviors in offspring (21).
MaTerials anD MeThODs
Participants
This study comprised of 49 ASD-diagnosed children (38 males, 11 
females, a male:female ratio of 3.4:1) from Jewish Israeli families, 
and their parents. Another six sets of parents of ASD-diagnosed 
children were enrolled, though no DNA samples were available 
from their children. DNA samples were collected in Israeli special 
education schools and treatment centers, by the Israeli Society for 
Autistic Children (ALUT).1
Many of the probands had already been diagnosed with ASD 
by independent clinicians; two trained clinicians confirmed the 
1 http://www.autismaroundtheglobe.org/countries/Israel.asp
TaBle 1 | Kir genotyping primers.
Kir Forward primers (5′–3′) amplicon (bp) annealing temp (°c) control gene alleles not detected
reverse primers (5′–3′)
2DS2 CGGGCCCCACGGTTT 240 60 CRP
GGTCACTCGAGTTTGACCACTCA
2DS4 TAGGCTCCCTGCAGTGCG 129 63 CAMP 2DS4*003
GAGTTTGACCACTCGTAGGGAGC 2DS4*004
2DS4*006
2DS4*007
2DS4*009
2DS1 CTTCTCCATCAGTCGCAT 102 53 CAMP
AGGGTCACTGGGAGCTGACAA
3DS1 GCCCAGCGCTGTGGTGCCTCGC 1958 71 CAMP 3DS1*047
CTGCAAGGGCACGCATCATGGA
2DL2 CTGGCCCACCCAGGTCG 173 60 CRP 2DL2*004
GGACCGATGGAGAAGTTGGCT
2DL1 AACTTCTCCATCAGTCGCATGAC 100 60 CRP
GGTCACTGGGAGCTGACAC
2DL3 CTTCATCGCTGGTGCTG 516 54 CAMP 2DL3*007
AGGCTCTTGGTCCATTACAA
3DL1 CTCCATCGGTCCCATGATGCT 1725 65 CAMP
CGCTCTCTCCTGCCTGAACCT
3DL2 CCCATGAACGTAGGCTCCG 130 54 CRP
CACACGCAGGGCAGGG
Expected PCR products, annealing temperature (°C), and allelic specificity are given per pair of primers. Primer reference is (22) for all KIRs except 2DS1, for which the primer 
reference is (23).
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diagnosis for autism or Pervasive Developmental Disorder-Not 
Otherwise Specified (PDD-NOS). All probands were diag-
nosed using the Autism Diagnostic Observation Scale-Generic 
(ADOS-G) and the Autism Diagnostic Interview-Revised (ADI-
R). In addition, parents were interviewed using the Vineland 
Adaptive Behavior Scales-second edition (Vineland™-II) survey 
interview edition (VABS).
Probands ranged in age between 25 months to 33 years and 
8 months. None of the subjects were known, according to paren-
tal reports, to have known genetic factors such as chromosomal 
aberrations, tuberous sclerosis, or other medical complications 
that could be related to autism. Parents were screened for psychi-
atric illness (including ASD); all results were found to be negative.
The Ethics Committee of the Israeli Health Ministry approved 
this study. All participants signed informed consent forms in 
advance.
genotyping
DNA was extracted from either peripheral blood or buccal cells 
using a commercial DNA purification kit (Epicentre’s Master 
Pure™, Madison, WI, USA).
The presence or absence of nine KIR genes known to inter-
act with specific HLA ligands was determined by SSP-PCR 
(sequence-specific primer polymerase chain reaction), as previ-
ously described (22, 23), using nine pairs of primers specific for 
these KIR genes. This mapping enables verification of presence 
or absence of a KIR, without discriminating specific heterozy-
gous or homozygote status. A 440/750-bp fragment of the CRP/
CAMP, respectively, was included in each PCR as an internal 
control. The following KIR genes were amplified under identical 
conditions: 2DL2, 2DL1, 3DL1, 2DS2, 2DS4, and 3DS1. Their 
PCR thermo-profile comprised 2 min at 92°C; then 25 s at 91°C, 
45 s at 65°C, and 45 s at 72°C for 4 cycles; 25 s at 91°C, 45 s at 
60°C, and 45 s at 72°C for 26 cycles; 25 s at 91°C, 60 s at 55°C, 
and 45 s at 72°C for 5 cycles, and 10 min at 72°C (an extension 
step, in the case of 3DL1 and 3DS1 was set to 2 min). Other KIR 
amplifications (for 2DL3, 3DL2, and 2DS1) were initiated with 
denaturation for 2 min at 92°C; then 25 s at 91°C, 45 s at 57°C, 
and 45 s at 72°C for 4 cycles; 25 s at 91°C, 45 s at 54°C, and 45 s at 
72°C for 26 cycles; 25 s at 91°C, 60 s at 50°C, and 45 s at 72°C for 
5 cycles, and 10 min at 72°C. All primer sequences, expected PCR 
products and allelic recoveries are listed in Table 1.
The distinction of HLA-C KIR ligand groups C1 (N80) and 
C2 (K80) was also performed by SSP-PCR. The common HLA-C 
forward primer was either paired with the C1 (N80) or C2 (K80) 
reverse primers, leading to an amplification product of 139 bp 
(Table  2). This mapping enables discrimination between het-
erozygous/homozygous status, i.e., C1–C1, C1–C2, or C2–C2. 
In each HLA PCR reaction, a 440-bp fragment of the CRP gene 
was included as an internal PCR control. The thermo-profile 
comprised an initial denaturation of 3 min at 95°C; then 10 s at 
95°C, 30 s at 65°C, and 45 s at 72°C for 10 cycles; 10 s at 95°C, 30 s 
at 58°C, 45 s at 72°C for 22 cycles, and 10 min at 72°C.
For HLA-C protocol validation, selected samples (n = 30; 10 
homozygous C1/C1, 10 homozygous C2/C2 and 10 heterozygous 
C1/C2) that had previously been typed for HLA-C at high reso-
lution by LIFECODES® HLA SSO Typing Kit (Gen-Probe, Inc.) 
(Later sequenced by Allele SEQR® HLA PCR/Sequencing Kit, 
Abbott Molecular) were analyzed by our SSP-PCR.
HLA-A BW4 and HLA-B BW4-I80/T80 were identified under 
the same conditions as HLA-C. Validation for HLA-A and B was 
also performed by selected samples previously genotyped by high 
TaBle 3 | inhibitory Kir frequencies in israeli families with at least 1 
asD-diagnosed child.
inhibitory Kir childasD Father childasD Mother Father Mother
2DL2 Mean 0.59 0.63 0.58 0.66 0.64 0.68
Z −0.577 −0.894 −0.408
Pearson’s r 0.487* 0.204 NR
2DL1 Mean 0.96 0.98 0.96 0.96 0.98 0.95
Z −1 0 −1
Pearson’s r 0.7* −0.039 NR
2DL3 Mean 0.86 0.84 0.87 0.89 0.84 0.88
Z −0.302 −0.333 −0.535
Pearson’s r 0.135 0.212 NR
3DL1 Mean 0.94 0.94 0.94 0.89 0.93 0.89
Z 0 −1.342 −0.707
Pearson’s r 0.645* 0.428* NR
3DL2 Mean 1 1 1 1 1 1
Z 0 0 0
Pearson’s r NR NR NR
Z = Wilcoxon Signed-Ranks Test value.
NR = not relevant.
*p ≤ 0.01.
TaBle 2 | Pcr primers for human leukocyte antigen (hla) amplification.
hla 
allotype
Direction Forward primers (5′–3′) amplicon 
(bp)
reverse primers (5′–3′)
HLA-C Forward CGCCGCGAGTCCGAGAGG 139
Reverse (C1: N80) GTTGTAGTAGCCGCGCAGG
Reverse (C2: K80) GTTGTAGTAGCCGCGCAGT
HLA-A  
BW4:I80
Forward CCATTGGGTGTCGGGTTTC 569
Reverse CTCTGGTTGTAGTAGCGGAGCGCG
HLA-B  
BW4:I80
Forward ACCCGGACTCAGAATCTCC 366
Reverse CTCTGGTTGTAGTAGCGGAGCGCG
HLA-B 
BW4:T80
Forward ACCCGGACTCAGAATCTCC 369
Reverse CTCTGGTTGTAGTAGCGGAGCAGG
Expected PCR product sizes are given. In the case of HLA-C, forward primer was 
either paired with the C1 (N80) or C2 (K80) reverse primers, leading to an amplification 
product of 139 bp.
F, forward; R, reverse.
TaBle 4 | activating Kir frequencies in israeli families with at least 1 
asD-diagnosed child.
activating Kir childasD Father childasD Mother Father Mother
2DS2 Mean 0.61 0.63 0.6 0.62 0.64 0.66
Z −0.302 −0.209 −0.209
Pearson’s r 0.523** 0.086 NR
2DS4 Mean 0.96 0.96 0.94 0.89 0.94 0.91
Z 0 −1.342 −0.707
Pearson’s r 0.478** 0.428** NR
2DS1 Mean 0.51 0.37 0.49 0.57 0.34 0.55
Z −1.528 −1.069 −2.268*
Pearson’s r 0.154 0.478** NR
3DS1 Mean 0.37 0.39 0.36 0.51 0.39 0.5
Z −0.728 −2* −1.279
Pearson’s r 0.281* 0.419** NR
Z = Wilcoxon Signed-Ranks Test value.
NR = not relevant.
*p ≤ 0.05.
**p ≤ 0.01.
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resolution methods. All primer sequences [based on Hong et al. 
(23)] and expected PCR products for HLA-A, -B, and -C genotyp-
ing are listed in Table 2.
All amplified SSP-PCR products were visualized by agarose 
gel electrophoresis using a non-mutagenic fluorescent reagent 
(“Novel Juice”; GeneDireX, Las Vegas City, NV, USA). Selected 
sample from each amplified band was sent for sequencing.
statistical analysis
The Wilcoxon Signed-Ranks test (p < 0.05) was determined using 
SPSS software. When combination of more than one factor to spe-
cific receptor was detected, some different aspects were detected. 
The first refers to all ligands equally, and compares the sum of 
all ligands (relevant to specific receptor) found in each person to 
determine the mean value. This is defined as “Ligand Composite” 
(Table 7). Secondly, an alternative designation of “Ligand One+” 
compares existence of at least one ligand to this specific receptor. 
This was the case in C1 + 2DL2/2DL3/2DS2, C2 + 2DL1/2DS1 
(Table  8). In contrast, for overall signaling (Table  9) and in 
the case of A_BW4 +  3DL1/3DS1 and B_BW4 +  3DL1/3DS1 
(Table 7) only the first option is shown. All HLAB genotyping 
analysis is described as “total,” meaning having I80/T80.
resUlTs
hla and Kirs Frequency comparison
Comparison of the nine different KIR genes and HLA frequen-
cies revealed several main differences between parents of autistic 
children (Tables 3–5).
The most surprising finding is higher frequency of HLA-
C2 allotypes in fathers of ASD children (mean 0.73 vs. 0.52, 
p = 0.038), in contrast to C1 frequencies, which were the same in 
both mothers and fathers (0.88 vs. 0.91) (Table 5). On the other 
hand, 2DS1, which is known to interact specifically with HLA-C2, 
was found in higher percentage (0.55 vs. 0.34, p = 0.022) in the 
maternal group (Table 4). Additionally 3DS1, with its specificity 
against BW4 allotypes, was found to be higher in mothers than in 
their ASD children (0.51 vs. 0.36, p = 0.044) (Table 4). Other KIR 
frequencies (2DL2, 2DL1, 2DL3, 3DL1, 3DL2, 2DS2, and 2DS4) 
were similar in both mothers and fathers, and corresponded 
with values expected in Asian populations.2 Most KIR and HLA 
frequencies in ASD children were similar to those detected in 
parents.
Positive correlation between parent (mother or father) 
and child, reflecting the likelihood of transferring the gene 
(Tables 3–5) were found relative to most of genes, which may 
reflect a high probability of homozygous genotyping for these 
genes.
Kir signaling Through hla Molecules
Relevant combinations between KIR receptors and their specific 
HLA ligands were detected (Table 6). ASD children did not exhibit 
2 http://www.allelefrequencies.net/kir6008a.asp
TaBle 5 | hla ligand frequencies in israeli families with at least 1 asD-diagnosed child.
hla ligand childasD Father childasD Mother Father Mother
HLAC1 Mean 0.86 0.9 0.83 0.85 0.88 0.91
Z −0.707 −0.333 −0.577
Pearson’s r 0.248 0.371** NR
HLAC2 Mean 0.65 0.72 0.68 0.57 0.73 0.52
Z −0.535 −1.342 −2.058*
Pearson’s r 0.353** 0.214 NR
HLA-A-BW4 Mean 0.33 0.37 0.3 0.28 0.36 0.3
Z −0.577 −0.229 −0.557
Pearson’s r 0.462** 0.134 NR
HLA-B-BW4 Mean 0.88 0.86 0.88 0.81 0.87 0.8
Z 0.33 1.272 1
Pearson’s r 0.203 0.248* NR
Z = Wilcoxon Signed-Ranks Test value.
NR = not relevant.
*p ≤ 0.05.
**p ≤ 0.01.
TaBle 6 | Frequency of each Kir detected and its corresponding ligand in israeli asD families, consisting of both parents and an asD-diagnosed child.
Kir childasD Father childasD Mother Father Mother
2DL2 + C1 Z −0.832 −1.342 −1.177
Pearson’s r 0.474** 0.259 NR
2DL1 + C2 Z −0.535 −1.091 −1.859
Pearson’s r 0.372** 0.176 NR
2DL3 + C1 Z 0 0 −0.426
Pearson’s r 0.227 0.321* NR
3DL1 + A_BW4 Z −0.227 −0.243 −0.392
Pearson’s r 0.148 0.156 NR
3DL1 + B_BW4 Z −0.302 −1.941* −1.225
Pearson’s r 0.283* 0.359** NR
2DS2 + C1 Z −0.577 −0.853 −1
Pearson’s r 0.511** 0.174 NR
2DS4 + A_BW4 Z −0.577 −0.243 −0.6
Pearson’s r 0.393** 0.156 NR
2DS4 + B_BW4 Z −0.302 −1.941* −1.279
Pearson’s r 0.211 0.359** NR
2DS1 + C2 Z −0.243 −0.775 −0.784
Pearson’s r 0.132 0.345** NR
3DS1 + A_BW4 Z 0 −0.577 −0.535
Pearson’s r 0.456** 0.12 NR
3DS1 + B_BW4 Z −0.728 −1.414 −0.853
Pearson’s r 0.25 0.295* NR
Z = Wilcoxon Signed-Ranks Test value.
NR, not relevant.
*p ≤ 0.05.
**p ≤ 0.01.
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high frequency of the combination HLA-C2 + KIR2DS1, despite 
elevated paternal HLA-C2 and maternal 2DS1 frequencies.
Correlational analysis between parent (mother or father) 
and child reflected the likelihood of transferring a gene with its 
corresponding ligand. Significant values were reported in most 
cases (Table 6). It is important to mention, these gene families 
are located on different autosomal chromosomes, supporting 
homozygous status for most of the genes.
The next evaluation involves the examination of particular 
HLA ligands with presence/absence of all relevant activating/
inhibitory KIR genes (Table 7). “Ligand Composite” analysis (see 
Materials and Methods) was compared between ASD children 
and their parents, as well as “Ligand One+” values (Table  8). 
Significant differences were found between parental groups in the 
case of C2 + 2DL1/2DS1 “Ligand One+” (p = 0.040).
Overall Balance of activation and 
inhibition
Final analysis (Table 9) presents a full view of the genotyping. 
It may allow insight to the overall expected interaction of KIR/
HLA in Israeli autistic individuals and their non-autistic parents, 
TaBle 7 | comparison of particular hla ligands with presence/absence of all relevant activating/inhibitory Kir genes in israeli asD families.
ligand composite childasD Father childasD Mother Father Mother
C1 + 2DL2/2DL3/2DS2 Z −0.363 −0.779 −1.178
C2 + 2DL1/2DS1 Z −0.213 −0.288 −0.704
A_BW4 + 3DL1/3DS1 Z −0.216 −0.378 −0.429
B_BW4 + 3DL1/3DS1 Z −0.382 −0.177 −0.28
Z = Wilcoxon Signed-Ranks Test value.
TaBle 8 | interactions of Kir and hla in autistic israeli patients and their parents, based on overall genotype mapping.
ligand one+ childasD Father childasD Mother Father Mother
C1 + 2DL2/2DL3/2DS2 Z −0.707 −0.333 −0.577
C2 + 2DL1/2DS1 Z −0.535 −1.342 −2.058*
Z = Wilcoxon Signed-Ranks Test value.
*p ≤ 0.05.
TaBle 9 | Overall ligand and interaction summaries.
childasD Father childasD Mother Father Mother
KIRs: activating Mean 2.4043 2.3191 2.3962 2.5849 2.2593 2.6667
Pearson’s r 0.331* 0.274* 0.104
t-Test 0.443 −1.121 −2.015*
KIRs: inhibitory Mean 4.3469 4.3878 4.3585 4.3962 4.4 4.3818
Pearson’s r 0.229 −0.023 0.153
t-Test −0.362 −0.286 0.155
Interactions: activating Mean 1.9149 1.9787 1.9245 2.0377 1.9259 2.1111
Pearson’s r 0.216 0.142 −0.119
t-Test −0.308 −0.636 −0.778
Interactions: inhibitory Mean 2.6939 2.7959 2.6981 2.6038 2.8214 2.6607
Pearson’s r 0.272 0.114 −0.099
t-Test −0.647 0.582 0.903
*p ≤ 0.05.
**p ≤ 0.01.
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based on all genotype mapping. Mothers have significantly 
higher levels of activating signals than their male counterparts 
(p = 0.049).
DiscUssiOn
Despite the increased attention garnered by autism research in 
recent years, the condition is currently diagnosed only after the 
infant reaches 2 or 3  years of age. Findings in autistic patients 
indicate multifactorial inheritance, while definitive genetic 
factors can be diagnosed in only a small percentage of cases. 
Immunological studies revealed a unique and distinguishing 
profile in ASD patients compared to controls. In the context of 
NK cells, altered gene expression, absolute number and function 
have been reported (7, 24, 25). Reports of modified NK function 
led us to investigate the highly polymorphic cell surface proteins 
on NK cells, called KIRs, to search for genetic background under-
lying the immune abnormalities. By interacting with MHC class 
I proteins expressed on all cell types, KIRs regulate the killing 
function of NK.
The most significant finding in this study is the unequal dis-
tribution of HLA-C2 (higher in fathers of ASD children) known 
to interact with KIR 2DS1 (higher in mothers of ASD children) 
to activate NK function. Analysis of “overall activation” (Table 9) 
signaling pointed to higher activation in maternal than paternal 
cohorts. Most HLA and KIR frequencies in ASD children ranged 
between those of their parents, indicating regular independent 
genetic inheritance from parents to children. This reinforced 
the importance of the specific HLA–KIR combinations between 
parents, though the mechanisms involved are still unclear. Our 
limitation in interpreting these findings lies in the absence of 
unusual prevalence of these genes or their combination in the 
ASD children, in comparison to their healthy parents.
Some reports correlated these initial interactions between 
parental cells as a possible mechanism for subsequent disease 
development or other complications. Hiby et  al. (26) reported 
an increased HLA-C2 frequency in different cohorts of affected 
pregnancies: (a) recurrent miscarriage (RM) couples and their 
conception products, (b) fetal growth restriction (FGR), and 
(c) preeclampsia. Conversely, lack of activating KIR (in women 
affected by RM) or increased inhibitory KIR (in women with 
7Gamliel et al. KIR/HLA Combinations in Autism
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preeclampsia) (26, 27) has already been reported. Specifically, 
KIR 2DS1 seemed to be protective because of its significant lack 
in RM women. We find this plausible, since activating KIR 2DS1 
compete with inhibitory KIR 2DL1 in interaction with HLA-C2, 
such that a predominance of KIR 2DS1 can overcome the strong 
inhibitory effect mediated by KIR 2DL1. All these findings sup-
port the importance of the innate immune system (mediated by 
maternal uterine NK and fetal trophoblast cells), modulated by 
KIR–HLA interaction to play a beneficial role in reproductive 
success.
Some papers have already pointed out differential segregation 
of KIR–HLA genes in autistic patients. Our study expands upon 
this by focusing within ASD families. Torres et al. (28) examined a 
large autistic cohort, revealing a highly significant increase in the 
activating KIR gene 2DS1 and its cognate HLA-C2 ligand. This 
increase in activating KIR may explain, at least partially, the high 
frequency of autoimmune diseases in autism patients. Guerini 
et  al. (29) compared ASD children to their non-ASD mothers 
and showed both that activating KIR/HLA combinations were 
increased and inhibitory KIR/HLA were reduced in ASD chil-
dren. This difference was proposed as having resulted from the 
genetic influence of the mothers, as these molecules’ expression 
and interaction are relevant in the surrounding uterus.
Ethnic populations are known to differ in KIR genotype fre-
quencies and genotype content (30). To the best of our knowledge, 
this is the first study to research KIR and HLA combinations in 
the Israeli Jewish population. As shown in the Allele Frequency 
Net Database,3 our geographical location has higher frequency 
of HLA-C2 (around 0.4–0.7 in Africa and the Middle East). 
However, we showed here a significant skewing between maternal 
and paternal C2 frequencies. It raises an interesting question, 
since HLA clusters map in autosomal chromosomes, leading to 
independent segregation without respect to gender.
Genotype mapping of this system has certain limitations. 
While theoretically all gene segments identified by our SSP-
PCR system may be expressed on the cell surface (meaning the 
functional KIR repertoire may depend on the KIR genotype), 
the transcription and translation processes may lead to different 
phenotype profiles. Another limitation of the SSP-PCR method 
in this context is the inability to determine the heterozygous/
homozygous status of each of these KIRs. Our future plans are to 
determine not only genotype, but also RNA and protein levels. 
Another point to take into account is that NK cell function is 
a very complicated process determined upon the balance of an 
array of receptors, of which KIR is only one family. Moreover, 
the affinity of these interactions may differ (e.g., KIR 2DL3: 
HLA-C1 interaction is thought to be weak, compared to KIR 
2DL2:HLA-C1 or KIR 2DL1:HLA-C2), such that one interaction 
may wield greater influence than another. It is also becoming 
increasingly clear that genetic factors, such as promoters and 
epigenetic mechanisms, are important in controlling NK cell 
receptor expression and function.
This study comprised a relatively small cohort of ASD-
affected families  –  though statistically verified based on the 
3 http://www.allelefrequencies.net/
minor allele frequency (MAF) of C2 (39.5%). In the absence of 
a control group, our findings were compared with the general 
population data of our geographical area. Additionally, the 
clinical patient data have not been thoroughly listed here, 
places limitations upon the reader in drawing parallels to 
other patient cohorts. The trends revealed in this preliminary 
investigation need to be further corroborated in ongoing and 
expanded research efforts.
Finally, we would like to emphasis another interesting aspect. 
On the one hand, different pregnancy complications (FGR, spon-
taneous abortion, placental abruption) are known to stem (at least 
to some degree) from immunological factors. On the other hand, 
perinatal factors unrelated to the immunological milieu may also 
be important in the pathogenesis of ASD. Certain complications 
during gestation were found to occur with increased frequency 
in mothers of ASD patients; an immunological basis has been 
suggested as underlying a portion of these. In some cases, inter-
mediate factors may play a partial role in the association (e.g., 
reduced birth weight).
cOnclUsiOn
The aim of our research was to genotype the KIR receptors and their 
relevant HLA ligands in autistic children and their non-autistic 
parents, in order to screen for possible unique combinations. The 
most interesting finding in this study is higher frequency of HLA-
C2 allotypes in the paternal group besides higher percentage of 
KIR 2DS1 in the maternal group. Such interaction may lead to 
NK activation. An absence of unusual prevalence of these genes 
or their combination in the ASD children, limited our ability to 
interpret these findings. Moreover, analysis of “overall activation” 
signaling pointed to higher activation in maternal than paternal 
cohorts.
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